Sinopharm Group Zhijun (Shenzhen) Pingshan Pharma Co. Ltd.

Primary objective: To evaluate the pharmacokinetic parameters of Pediatric Faropenem Sodium Granules (Specification: 0.05g) produced by Sinopharm Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd. and Pediatric Faropenem Sodium Granules (Trade name: Feromu®, Specification: 0.05g) certified by Maruho Co., Ltd. by using a single-center, randomized, open, single-dose, two-preparation, two-period, self-crossover design, and to evaluate the bioequivalence of the reference preparation and the test preparation under fasting and postprandial conditions. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

1. Main purpose: To evaluate the pharmacokinetic parameters of sacubitril-valsartan sodium tablets (specification: 200 mg) produced by Sinopharm Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd. and sacubitril-valsartan sodium tablets (trade name: Nuxintu®, specification: 200 mg) certified by Novartis Pharma Schweiz AG using a single-center, randomized, open, single-dose, four-cycle, two-sequence, completely repeated crossover design, and to evaluate the bioequivalence of the reference preparation and the test preparation under fasting and postprandial conditions. 2. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

The aim of this study was to investigate the pharmacokinetic characteristics of fasting and postprandial oral montelukast sodium chewable tablets (5 mg/tablet × 1 tablet) developed and produced by Sinopharm Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd., and to compare the pharmacokinetic parameters of the two preparations with Merck Sharp & Dohme B.V.'s montelukast sodium chewable tablets (Singulair®, 5 mg/tablet × 1 tablet) as the reference preparation, and to evaluate the bioequivalence of the two preparations in humans.